hero section gradient
16 handpicked stocks

Fortress America: Insulated From Trade Wars

Puma's recent profit warning, driven by U.S. tariffs, highlights the significant financial risks associated with global trade disputes. This event underscores a potential investment opportunity in companies with primarily domestic supply chains that are better insulated from such geopolitical volatility.

Author avatar

Han Tan | Market Analyst

Published on July 25

Your Basket's Financial Footprint

Summary and investor takeaways for the provided stock basket market capitalisation data.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering steadier performance and closer tracking to broad-market behaviour.
  • Use as a core allocation to anchor a diversified portfolio, not as a speculative growth sleeve.
  • Expect steady, long-term appreciation rather than rapid, short-term gains; growth is generally moderate.
Total Market Cap
  • TSCO: $29.03B

  • XPO: $16.02B

  • CSL: $14.33B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Recent events like Puma's tariff-driven profit warning highlight the risks facing companies with global supply chains. We've identified businesses with predominantly domestic operations that may offer greater stability during trade disputes and geopolitical tensions.

2

What You Need to Know

This group focuses on companies operating primarily within U.S. borders, spanning domestic logistics, construction materials, and U.S.-based manufacturing. These businesses face reduced exposure to import duties and international shipping complexities that can impact earnings.

3

Why These Stocks

Each company was handpicked by professional analysts for their defensive positioning against tariff-related market shocks. Their operational structures offer potential insulation from the headline risks affecting globally-oriented firms, making them tactical portfolio additions.

Why You'll Want to Watch These Stocks

🛡️

Trade War Protection

While global companies face tariff headwinds, these domestic-focused businesses offer potential shelter from international trade disputes that can devastate earnings overnight.

🏭

Made in America Advantage

Companies with U.S.-based supply chains are positioned to benefit from reshoring trends and avoid the supply chain disruptions that plague internationally dependent competitors.

📈

Stability in Uncertainty

When headlines about trade wars send global stocks tumbling, these domestically insulated companies may offer the earnings predictability that investors crave during volatile times.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions